Publication | Closed Access

A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria–tetanus–pertussis vaccine

VaccinologyVaccinationVaccine DevelopmentImmunologyTherapeutic VaccineT Cell ImmunityCd4 T Cell ResponsesDiphtheria–tetanus–pertussis VaccineTh1/th2 Immune ResponseCpg-containing OligodeoxynucleotideMedicineVaccine ResearchVaccine Design